In an in vivo “stress test” in which tumor burden is escalated to reveal CAR T-cell functional limits, PRDM1 KO CAR T-cells showed comparable antitumor activity to AAVS1 KO CAR T-cells (Fig. 4C and D). This evidence concerns the gene PPP1R12C and neoplasm.